Conflict-of-interest disclosure: N.S.G. reports research funding from Genentech and Tessa Therapeutics, and honoraria/consulting/advisory board fees from ADC Therapeutics, Genentech, Kite, Novartis, Tessa Therapeutics, and Seattle Genetics. P.T. reports honoraria/consulting/advisory board fees from TG Therapeutics, ADC Therapeutics, Genentech, GenMab, and Lilly USA. B.C. reports research funding from Genentech, Acerta, Triphase, MorphoSys, Seagen, Millenium, Bristol Myers Squibb (BMS), and F. Hoffman-La Roche, and advisory board fees from Genentech and ADC Therapeutics. P.R.G. reports consultancy services to Kite Pharma, BMS, and Rafael Pharma, and serving on the advisory boards of Pharmacyclics LLC, ADC Therapeutics, Cellectar Biosciences, and Ono Pharma. R.K. received advisory board fees from BMS, Gilead Sciences/Kite Pharma, Janssen, Karyopharm, Pharmacyclics, MorphoSys, Epizyme, Genentech/Roche, EUSA, and Calithera; grants/research support from BMS, Takeda, BeiGene, Gilead Sciences/Kite, and Calithera; and speakers bureau fees from AstraZeneca, BeiGene, and MorphoSys. S.K.B. reports honoraria from Acrotech, Affimed, Daiichi Sankyo, Kyowa Kirin, Janssen, and Seagen. N.L.B. reports research funding from ADC Therapeutics, Autolus, BMS, Celgene, Forty Seven, Genentech, Immune Design, Janssen, Merck, Millennium, Pharmacyclics, Affirmed Therapeutics, Dynavax, Gilead, MedImmune, and Novartis, and consulting/ad board fees from Kite Pharma, Pfizer, ADC Therapeutics, Roche/Genentech, Seattle Genetics, BTG, and Acerta. A.J.O. reports funding from GenMab, Precision Bio, Adaptive Biotechnologies, Celldex, Acrotech Biopharma, Schrodinger, TG Therapeutics, and Genentech. N.E. reports research funding from BeiGene; speakers bureau fees from Incyte, BeiGene, and Novartis; and honoraria/consulting/advisory board fees from Merck, ADC Therapeutics, Lilly, Ipsen, and Novartis. The remaining authors declare no competing financial interests.